HERNANDEZ PEDRO, NORMA YANET

Publicaciones ORCID

2026

Correction: Rodríguez-Bautista et al. Immune Milieu and Genomic Alterations Set the Triple-Negative Breast Cancer Immunomodulatory Subtype Tumor Behavior. <i>Cancers</i> 2021, <i>13</i>, 6256 Cancers

Progression phenotypes to anti–PD-(L)1 therapy and subsequent management of patients with metastatic NSCLC: A real-world cohort study Cancer Treatment and Research Communications

2025

Correction: Rodríguez-Bautista et al. Immune Milieu and Genomic Alterations Set the Triple-Negative Breast Cancer Immunomodulatory Subtype Tumor Behavior. <i>Cancers</i> 2021, <i>13</i>, 6256 Cancers

Correction: Hernández-Pedro et al. Impact of Tyrosine Kinase Inhibitors on the Immune Response to SARS-CoV-2 Vaccination in Patients with Thoracic Malignancies. Vaccines 2023, 11, 1612 Vaccines

2024

Real-World Survival Outcomes in Non–Small Cell Lung Cancer: The Impact of Genomic Testing and Targeted Therapies in a Latin American Middle-Income Country JCO Global Oncology

Prevalence of pathogenic or likely pathogenic germline variants in cancer predisposition genes among selected patients with lung adenocarcinoma: The GERMLUNG study Lung Cancer

2023

Impact of KRASG12D subtype and concurrent pathogenic mutations on advanced non-small cell lung cancer outcomes Clinical and Translational Oncology

A Novel Combination of Sotorasib and Metformin Enhances Cytotoxicity and Apoptosis in KRAS-Mutated Non-Small Cell Lung Cancer Cell Lines through MAPK and P70S6K Inhibition International Journal of Molecular Sciences

LKB1 Loss Assessed by Immunohistochemistry as a Prognostic Marker to First-Line Therapy in Advanced Non-Small-Cell Lung Cancer Current Oncology

Nitroglycerin Plus Whole Intracranial Radiation Therapy for Brain Metastases in Patients With Non-Small Cell Lung Cancer: A Randomized, Open-Label, Phase 2 Clinical Trial International Journal of Radiation Oncology Biology Physics